A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the Db-Ig platform, which...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Rau, Alexander, Kocher, Katharina, Rommel, Mirjam, Kühl, Lennart, Albrecht, Maximilian, Gotthard, Hannes, Aschmoneit, Nadine, Noll, Bettina, Olayioye, Monilola A., Kontermann, Roland E., Seifert, Oliver
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993124/
https://ncbi.nlm.nih.gov/pubmed/33752566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2021.1902034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados